Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 366 Cr.
- Current Price ₹ 310
- High / Low ₹ 328 / 222
- Stock P/E 24.0
- Book Value ₹ 69.8
- Dividend Yield 0.00 %
- ROCE 18.1 %
- ROE 20.0 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 208 days to 144 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last 3 years: -5.87%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 22 | 32 | 45 | 87 | 103 | |
| 19 | 25 | 36 | 72 | 82 | |
| Operating Profit | 3 | 6 | 8 | 15 | 21 |
| OPM % | 12% | 20% | 18% | 17% | 21% |
| 1 | 1 | 2 | 8 | 7 | |
| Interest | 0 | 0 | 1 | 4 | 4 |
| Depreciation | 0 | 0 | 1 | 5 | 6 |
| Profit before tax | 3 | 7 | 9 | 14 | 18 |
| Tax % | -32% | 8% | 32% | 23% | |
| 4 | 6 | 6 | 10 | 14 | |
| EPS in Rs | 4.94 | 5.24 | 5.51 | 10.22 | 13.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 59% |
| TTM: | 86% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 44% |
| TTM: | 86% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 38% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 18% |
| Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 8 | 12 | 12 | 12 | 12 |
| Reserves | -3 | 34 | 41 | 53 | 69 |
| 2 | 8 | 18 | 54 | 59 | |
| 7 | 9 | 16 | 37 | 47 | |
| Total Liabilities | 14 | 63 | 87 | 156 | 187 |
| 1 | 3 | 21 | 44 | 46 | |
| CWIP | 0 | 5 | 4 | 2 | 2 |
| Investments | 0 | 3 | 4 | 11 | 9 |
| 12 | 51 | 58 | 99 | 130 | |
| Total Assets | 14 | 63 | 87 | 156 | 187 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -0 | -19 | 2 | -10 | |
| -0 | -10 | -20 | -14 | |
| 1 | 42 | 11 | 20 | |
| Net Cash Flow | 0 | 14 | -7 | -4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 83 | 139 | 110 | 116 |
| Inventory Days | 95 | 129 | 156 | 226 |
| Days Payable | 134 | 87 | 94 | 119 |
| Cash Conversion Cycle | 44 | 182 | 173 | 224 |
| Working Capital Days | 49 | 275 | 205 | 144 |
| ROCE % | 23% | 15% | 18% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
1 Jan - Acquired 9.04% of Trident Mediquip for ~Rs4.42 Cr; stake increased to 60.04%.
- Closure of Trading Window 31 Dec
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 30 Dec
-
Announcement under Regulation 30 (LODR)-Allotment
27 Dec - Allotment of 135,000 equity shares at Rs.266 each (Rs.2,69,32,500) upon warrant conversion on Dec 27, 2025.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. On December 27, 2025, In Terms Of Second Proviso To Regulation 30(6) Of SEBI (LODR) Regulations, 2015
27 Dec - 135,000 warrants converted to equity on Dec 27, 2025; Rs.2,69,32,500 received; post-capital 11,933,000 shares.
Annual reports
Concalls
-
Nov 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Jul 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Jan 2023TranscriptAI SummaryPPT
Business Overview:[1]
TFL is a pharmaceutical Company with business operations spanning formulations under its own brands, loan licence model and contract manufacturing model.
a) Pharmaceutical formulations export:
Company has a presence in 40 countries, including African, Latin America, and East
Asian countries, with ~945 registered export market products, and ~2016 export market products are under registration
b) Contract manufacturing:
Company follows an Asset-light third-party contract manufacturing model thus entailing limited direct investment in manufacturing capacities